Alpha 2.0
Login Register
» Authors » Bassam Abdulkarim

Bassam Abdulkarim

Explore the profile of Bassam Abdulkarim including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 47
Citations 1032
Followers 0
Related Specialties
Oncology
Radiology
Neurology
Top 10 Co-Authors
Siham Sabri
Marie-Christine Guiot
Valerie Panet-Raymond
Paul Daniel
Sunita Ghosh
George Shenouda
Luis Souhami
Kevin Petrecca
Yaoxian Xu
Ahmad Chaddad
Published In
Int J Radiat Oncol Biol Phys
Radiat Oncol
Neuro Oncol
Oncogene
Oncotarget
Affiliations
Soon will be listed here.
Recent Articles
1.
Growth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected locally advanced non-small cell lung cancer treated with chemoradiotherapy
Di Pastena F, Pond G, Tsakiridis E, Gouveia A, Ahmadi E, Biziotis O, et al.
Radiat Oncol . 2024 Nov; 19(1):155. PMID: 39511611
Introduction: Growth differentiation factor 15 (GDF15) is a cytokine of the TGFβ family. Here, we analyzed GDF15 levels in patients with locally advanced non-small cell lung cancer (LA-NSCLC) who participated...
2.
Synergistic Dual Targeting of Thioredoxin and Glutathione Systems Irrespective of p53 in Glioblastoma Stem Cells
Jamali F, Lan K, Daniel P, Petrecca K, Sabri S, Abdulkarim B
Antioxidants (Basel) . 2024 Oct; 13(10). PMID: 39456455
Glioblastoma (GBM) is an incurable primary brain cancer characterized by increased reactive oxygen species (ROS) production. The redox-sensitive tumor suppressor gene , wild-type (wt) for 70% of patients, regulates redox...
3.
Pro-Oxidant Auranofin and Glutathione-Depleting Combination Unveils Synergistic Lethality in Glioblastoma Cells with Aberrant Epidermal Growth Factor Receptor Expression
Martinez-Jaramillo E, Jamali F, Abdalbari F, Abdulkarim B, Jean-Claude B, Telleria C, et al.
Cancers (Basel) . 2024 Jul; 16(13). PMID: 39001381
Glioblastoma (GBM) is the most prevalent and advanced malignant primary brain tumor in adults. GBM frequently harbors epidermal growth factor receptor (EGFR) wild-type () gene amplification and/or activating mutation. EGFR-driven...
4.
Transitioning to Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: Trends and Surgical Outcomes in a Regionalized Pulmonary Oncology Network
Pilon Y, Rokah M, Seitlinger J, Sepesi B, Rayes R, Cools-Lartigue J, et al.
Clin Lung Cancer . 2024 Feb; 25(3):e133-e144.e4. PMID: 38378398
Background: Several regulatory agencies have approved the use of the neoadjuvant chemo-immunotherapy for resectable stage II and III of non-small cell lung cancer (NSCLC) and numerous trials investigating novel agents...
5.
Phase II trial of concurrent sunitinib, temozolomide, and radiotherapy with adjuvant temozolomide for newly diagnosed MGMT unmethylated glioblastoma
Faye M, Easaw J, de Robles P, Agnihotram R, Torres-Vasquez A, Lamonde F, et al.
Neurooncol Adv . 2023 Sep; 5(1):vdad106. PMID: 37771465
Background: The overall prognosis of glioblastoma (GBM) remains dismal, particularly for patients with unmethylated O6-methylguanine-DNA-methyltransferase () promoter. In this phase II trial, we tested the combination of the antiangiogenic agent...
6.
Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non-small cell lung cancer (NSCLC) through inhibition of HIF-1α
Biziotis O, Tsakiridis E, Ali A, Ahmadi E, Wu J, Wang S, et al.
Mol Oncol . 2023 Aug; 17(11):2235-2256. PMID: 37584455
Non-small cell lung cancer (NSCLC) has a poor prognosis, and effective therapeutic strategies are lacking. The diabetes drug canagliflozin inhibits NSCLC cell proliferation and the mammalian target of rapamycin (mTOR)...
7.
Targeted Intraoperative Radiation Therapy during Breast-Conserving Surgery for Patients with Early Stage Breast Cancer: A Phase II Single Center Prospective Trial
Martinez C, Meterissian S, Saidi A, Tremblay F, Meguerditchian A, Fleiszer D, et al.
Adv Radiat Oncol . 2023 Jul; 8(5):101236. PMID: 37408681
Purpose: Patients with early stage breast cancer (ESBC) are conventionally treated with breast-conserving surgery (BCS) followed by whole-breast external beam radiation therapy (EBRT). The emergence of targeted intraoperative radiation therapy...
8.
Stereotactic ablative radiotherapy before resection to avoid delay for early-stage lung cancer or oligometastases during the COVID-19 pandemic: Pathologic outcomes from the SABR-BRIDGE protocol
Kidane B, Gerard I, Spicer J, Kim J, Fiset P, Wawryko P, et al.
Cancer . 2023 May; 129(18):2798-2807. PMID: 37221679
Background: During coronavirus disease 2019 (COVID-19)-related operating room closures, some multidisciplinary thoracic oncology teams adopted a paradigm of stereotactic ablative radiotherapy (SABR) as a bridge to surgery, an approach called...
9.
Use of radiation therapy among patients with Extensive-stage Small-cell lung cancer receiving Immunotherapy: Canadian consensus recommendations
Sun A, Abdulkarim B, Blais N, Greenland J, Louie A, Melosky B, et al.
Lung Cancer . 2023 Mar; 179:107166. PMID: 36944282
Objectives: Thoracic radiation therapy (TRT) and prophylactic cranial irradiation (PCI) are commonly used in the management of extensive-stage small-cell lung cancer (ES-SCLC); however, Phase III trials of first-line immunotherapy often...
10.
Detection of temozolomide-induced hypermutation and response to PD-1 checkpoint inhibitor in recurrent glioblastoma
Daniel P, Meehan B, Sabri S, Jamali F, Sarkaria J, Choi D, et al.
Neurooncol Adv . 2022 Jul; 4(1):vdac076. PMID: 35795471
Background: Despite aggressive upfront treatment in glioblastoma (GBM), recurrence remains inevitable for most patients. Accumulating evidence has identified hypermutation induced by temozolomide (TMZ) as an emerging subtype of recurrent GBM....